Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, China.
Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing, China.
Colorectal Dis. 2017 Nov;19(11):962-972. doi: 10.1111/codi.13900.
The application of complete mesocolic excision (CME) in colon cancer is controversial. We performed a meta-analysis to compare the safety, quality and effect of CME with non-complete mesocolic excision (NCME) in patients with colon cancer.
We searched PubMed, ScienceDirect, the Cochrane Library and Scopus to identify studies comparing CME with NCME in colon cancer. We focused on three study outcome areas: safety (operation time, blood loss, complications, mortality); quality (large bowel length, distance from the tumour to the high vascular tie, area of mesentery, total lymph nodes); and effect (long-term survival).
A total of 8586 patients from 12 studies were included in the meta-analysis. CME was associated with greater intra-operative blood loss [weighted mean difference (WMD) 79.87, 95% CI: 65.88-93.86], more postoperative surgical complications (relative risk 1.23, 95% CI: 1.08-1.40), longer large bowel resection (WMD 47.06, 95% CI: 10.49-83.62), greater distance from the tumour to the high vascular tie (WMD 17.51, 95% CI: 15.16-19.87), larger area of mesentery (WMD 36.09, 95% CI: 18.06-54.13) and more lymph nodes (WMD 6.13, 95% CI: 1.97-10.28) than NCME. CME also had positive effects on 5-year survival [hazard ratio (HR) 0.33, 95% CI: 0.13-0.81], 3-year survival (HR 0.58, 95% CI: 0.39-0.86) and 3-year survival for Stage III disease (HR 0.69, 95% CI: 0.60-0.80) compared with NCME.
Limited evidence suggests that CME is a more effective strategy for improving specimen quality and survival but with a higher complication rate.
完整结肠系膜切除术(CME)在结肠癌中的应用存在争议。我们进行了一项荟萃分析,比较了 CME 与非完整结肠系膜切除术(NCME)在结肠癌患者中的安全性、质量和效果。
我们检索了 PubMed、ScienceDirect、Cochrane 图书馆和 Scopus,以确定比较 CME 与 NCME 在结肠癌中的研究。我们关注了三个研究结果领域:安全性(手术时间、出血量、并发症、死亡率);质量(大肠长度、肿瘤至高位血管结扎处的距离、系膜面积、总淋巴结数);效果(长期生存)。
共有 12 项研究的 8586 名患者纳入荟萃分析。CME 与术中出血量增加相关[加权均数差(WMD)79.87,95%可信区间:65.88-93.86],术后手术并发症更多(相对风险 1.23,95%可信区间:1.08-1.40),大肠切除更长[WMD 47.06,95%可信区间:10.49-83.62],肿瘤至高位血管结扎处的距离更远[WMD 17.51,95%可信区间:15.16-19.87],肠系膜面积更大[WMD 36.09,95%可信区间:18.06-54.13],淋巴结更多[WMD 6.13,95%可信区间:1.97-10.28]。与 NCME 相比,CME 对 5 年生存率[风险比(HR)0.33,95%可信区间:0.13-0.81]、3 年生存率(HR 0.58,95%可信区间:0.39-0.86)和 3 年 III 期疾病生存率(HR 0.69,95%可信区间:0.60-0.80)也有积极影响。
有限的证据表明,CME 是一种提高标本质量和生存率的更有效策略,但并发症发生率更高。